@Article{,
AUTHOR = {Ben Tran, Joe McKendrick},
TITLE = {Metastatic urachal cancer responding to FOLFOX chemotherapy},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {17},
YEAR = {2010},
NUMBER = {2},
PAGES = {5120--5123},
URL = {http://www.techscience.com/CJU/v17n2/62067},
ISSN = {1488-5581},
ABSTRACT = {Metastatic urachal cancer is a rare disease and subsequently, 
does not have a defi ned systemic treatment. Although 
urachal cancer is most commonly adenocarcinoma and 
histologically similar to colon cancer, treatment selection 
is usually based upon location (the proximity of the 
urachus to the bladder) with bladder cancer regimens the 
most commonly prescribed. We report a case of metastatic 
urachal cancer where the immunohistochemical profi le’s 
similarities to colon cancer led to treatment with colon 
cancer specifi c chemotherapy. Our case is the fi rst to 
report urachal cancer treated with and responding to 
modifi ed FOLFOX6. In the age of targeted therapy, 
where molecular biology drives treatment selection, our 
case highlights that in rare tumors, when evidence is often 
lacking, a common sense approach can often prevail.},
DOI = {}
}